Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
Stopped The study aimed to include multiple countries in Latin America, but only Brazil was feasible, making the intended ethnic and racial design unviable. Activities were closed and no sites were opened for recruitment.
Conditions
- Prostate Cancer
- Castrate Resistant Prostate Cancer
- Homologous Recombination Deficiency
Interventions
- DRUG: Niraparib/Abirate rone acetate fixed-dose combination
- DRUG: Prednisone
Sponsor
Latin American Cooperative Oncology Group
Collaborators